Eric J. Topol

TL;DR: Clinical management of AF is variable, but in GUSTO-3 there was a strong trend towards lower mortality associated with the use of class I antiarrhythmic agents or sotalol, and none of the specific antiarrHythmic therapies was associated with a higher chance of having sinus rhythm at discharge or before deterioration to in-hospital death.

TL;DR: Platelets are not necessarily systemically activated during the prereperfusion phase of AMI, and for each agonist used and surface antigen measured, there was a cohort of patients with AMI within the normal or even below normal range of platelet status.

TL;DR: The adjunctive administration of AR-C69931MX blocked ADP-mediated platelet aggregation and recruitment and prevented platelet-mediated thrombosis, resulting in prolongation of reperfusion time and a decrease in reocclusion and cyclic flow variations.

TL;DR: After acute intervention, an infarct vessel with intermittent patency or suboptimal flow is associated with a high rate of reocclusion, and residual stenosis greater than or equal to 50% appears to predict a high incidence of negative in-hospital clinical outcomes and the need for subsequent revascularization.

TL;DR: Cardiogenic shock continues to be associated with high mortality in thrombolytic-treated patients and lower mortality observed in the U.S.A. supports consideration for percutaneous and surgical revascularization.